ReviewPLoS neglected tropical diseases2026
Emergence of Marburg virus disease in Ethiopia: Implications for public health preparedness and its impact on Ethiopia's health system.
Review in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMarburg virus disease (MVD) is a rare but highly lethal viral hemorrhagic fever (VHF) caused by Marburg virus (MARV) and Ravn virus (RAVV). While MVD has historically been limited to specific areas of sub-Saharan Africa, recent outbreaks in previously unaffected countries indicate an expanding ecological and epidemiological risk. In November 2025, Ethiopia confirmed its first-ever MVD outbreak, constituting a significant national and regional public health emergency.
methodsThis narrative review synthesizes publicly available epidemiological data, government situation reports, and official communications from the Ethiopian Ministry of Health (MoH), Ethiopian Public Health Institute (EPHI), Africa Centres for Disease Control and Prevention (Africa CDC), and the World Health Organization (WHO).
resultsThe outbreak was initially detected in Jinka town, South Ethiopia Region, an area bordering Kenya and South Sudan. As of 25 January 2026, more than 3,800 diagnostic tests were conducted, leading to a total of 19 cases comprising 14 confirmed (including nine deaths) and five probable (all deaths) and five recoveries from MVD in the country's South Ethiopia and Sidama regions, which were reported. A total of 857 contacts listed for monitoring all had completed their 21-day follow-up as of 25 January 2026. Ethiopia's response included rapid notification, laboratory confirmation, activation of incident management systems, deployment of mobile high-biosafety laboratories, establishment of isolation and treatment centers, and issuance of national clinical management guidelines. International partners provided technical, financial, and logistical support. However, the outbreak exposed ongoing challenges, including health system fragility, workforce shortages, misinformation, funding limitations, and heightened cross-border transmission risk.
conclusionThe emergence of MVD in Ethiopia represents a pivotal moment for national and regional health security. Sustained containment will require strengthened surveillance, community engagement, cross-border collaboration, and integrated One Health approaches. Long-term investment in resilient health systems and coordinated regional preparedness is essential to prevent future spillover events and protect vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.